A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A phase 1/2 trial of Emi-Le in triple-negative breast cancer, endometrial cancer, ovarian cancer and salivary gland cancers, run by Day One Biopharmaceuticals, Inc., now recruiting.
Overview
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT05377996 by Day One Biopharmaceuticals, Inc., with 360 participants planned, started 2022-08-15 and due to reach its primary completion in 2027-02. Interventions recorded: Emi-Le.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Shares Endometrial cancer, Triple-negative breast cancer (TNBC), Ovarian cancer and the tag pipeline.
- TrialDAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Shares Day One Biopharmaceuticals and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialClinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
Shares Salivary gland cancers and the tag pipeline.
- TrialStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Shares Triple-negative breast cancer (TNBC), Ovarian cancer and the tag pipeline.